Oncology – Page 26

Bridging the Gap: Addressing Inconsistent Reporting of Venous and Arterial Thrombotic Events in Cancer Clinical Trials

By MedXY 09/08/2025

Venous and arterial thrombotic events in cancer patients are underreported in clinical trials, impairing risk assessment and prevention strategies. Uniform and comprehensive reporting is imperative to improve patient outcomes and guide therapeutic decisions.

Clinical Updates Diabetes & Endocrinology news Oncology

Type 2 Diabetes and Colorectal Cancer: Immune Landscape Shapes Risk and Survival Outcomes

By MedXY 09/08/2025

Type 2 diabetes increases colorectal cancer risk and worsens survival, particularly in tumors with low immune cell infiltration, highlighting the interplay between metabolic and immune factors in cancer progression and prognosis.

Clinical Updates news OB/GYN & Women's Health Oncology

EPIK-O Trial Explores Alpelisib plus Olaparib Versus Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian Cancer Without BRCA Mutation

By MedXY 09/08/2025

The phase III EPIK-O trial showed no progression-free survival benefit of alpelisib plus olaparib over chemotherapy in BRCA wild-type platinum-resistant or refractory high-grade serous ovarian cancer, highlighting treatment challenges and biomarker insights.

Clinical Updates news Oncology

FDA Approval of Trastuzumab Deruxtecan: Advancing Treatment for HR-Positive HER2-Low and Ultralow Metastatic Breast Cancer

By MedXY 09/08/2025

Trastuzumab deruxtecan (T-DXd) gains FDA approval for HR-positive, HER2-low and HER2-ultralow unresectable or metastatic breast cancer after endocrine therapy progression, offering significant progression-free survival benefits over chemotherapy.

Family Medicine & Nutrition news Oncology

10 Habits That Cancer Cells Fear: Building Your Body’s Natural Defense

By MedXY 09/08/2025

Explore ten evidence-based lifestyle habits that significantly reduce cancer risk and empower your body’s natural defenses against cancer development.

Clinical Updates Oncology Specialties

Updated Phase III HARMONi Trial Data Reveal Enhanced Survival Benefits of Ivonescimab in NSCLC

By MedXY 09/07/2025

Recent updates from the global Phase III HARMONi study demonstrate envafolimab’s significant improvement in overall and progression-free survival in NSCLC, with consistent benefits across diverse populations, reinforcing its emerging role in lung cancer therapy.

Cardiology news Oncology Specialties

Sacubitril-Valsartan for Cardiac Protection During Breast Cancer Therapy: Insights from the PRADA II Trial

By MedXY 09/06/2025

The PRADA II trial evaluated sacubitril-valsartan for preventing cardiac dysfunction during anthracycline-based breast cancer therapy. While it did not significantly preserve left ventricular ejection fraction, improvements in myocardial strain and cardiac biomarkers suggest a potential role in cardioprotection.

Cardiology news Oncology Specialties

MODICA: A Mitochondrial Peptide Shielding the Heart Against Doxorubicin-Induced Cardiotoxicity

By MedXY 09/06/2025

MODICA, a mitochondrial sORF-encoded peptide, protects cardiac function from doxorubicin toxicity by inhibiting VDAC oligomerization, reducing apoptosis and fibrosis, highlighting a novel cardioprotective therapeutic target.

Clinical Updates news Oncology

Targeting Immunosenescence: Combining Senolytics with Immunotherapy Improves Outcomes in Head and Neck Squamous Cell Carcinoma

By MedXY 09/04/2025

A phase 2 trial reveals that senolytic agents combined with anti-PD-1 immunotherapy enhance pathological response rates in head and neck squamous cell carcinoma by mitigating immunosenescence, with promising safety profiles.

Clinical Updates news OB/GYN & Women's Health Oncology Specialties

Patritumab Deruxtecan Shows Promising Efficacy in HR+HER2− Advanced Breast Cancer After CDK4/6 Inhibitor Failure: Insights from ICARUS-BREAST01 Phase 2 Trial

By MedXY 09/04/2025

The ICARUS-BREAST01 phase 2 trial demonstrated patritumab deruxtecan's efficacy and manageable safety in HR+HER2− metastatic breast cancer post-CDK4/6 inhibitors, highlighting key biomarkers linked to response and resistance.

news Oncology Pathology & Lab Medicine Specialties

Circulating Tumor DNA as a Biomarker to Guide Timing of CDK4/6 Inhibitor Therapy in Advanced ER+ HER2− Breast Cancer

By MedXY 09/04/2025

Pretreatment circulating tumor DNA levels can predict which patients with advanced ER-positive, HER2-negative breast cancer benefit more from first-line CDK4/6 inhibitor therapy, supporting personalized treatment strategies.

news Oncology Specialties

Targeting Dormant Tumor Cells: A Promising Strategy to Prevent Breast Cancer Recurrence

By MedXY 09/04/2025

A phase 2 randomized trial demonstrates that targeting dormant disseminated tumor cells with hydroxychloroquine and everolimus is safe, feasible, and reduces minimal residual disease, potentially improving recurrence-free survival in breast cancer survivors.

Medical News news Oncology Specialties

Unmasking Brain Cancer’s Sugar Secret: How Glioblastoma Hijacks Glucose to Fuel Tumor Growth and Resist Therapy

By MedXY 09/04/2025

A groundbreaking Nature study reveals how glioblastoma reprograms glucose metabolism, exploiting environmental serine to accelerate growth and resist treatment, offering new metabolic targets for personalized therapies.

news Oncology Specialties

Immunosuppressive Roles of Tumour-Infiltrating B Cells in Intrahepatic Cholangiocarcinoma and Implications for Chemoimmunotherapy Outcomes

By MedXY 09/04/2025

This article reviews the immunosuppressive mechanisms of tumour-infiltrating B cells in intrahepatic cholangiocarcinoma (iCCA), their impact on prognosis, and potential to enhance chemoimmunotherapy efficacy by restoring B-cell function and promoting tertiary lymphoid structures.

news Oncology Specialties

Decoding Irinotecan Toxicity: The Role of Bacteroides intestinalis and Tryptophan Metabolites

By MedXY 09/04/2025

This article reviews how Bacteroides intestinalis influences intestinal sensitivity to irinotecan toxicity via the tryptophan metabolite indole-3-acetate, uncovering novel biomarkers and therapeutic insights for chemotherapy-induced diarrhoea.

news Oncology Specialties

Local Recurrence and Survival Outcomes in Non-Lentigo Maligna and Non-Acral Lentiginous Melanoma In Situ: Evidence from a 30-Year Cohort Study

By MedXY 09/03/2025

This retrospective cohort study evaluates local recurrence and survival in non-LM/non-ALM melanoma in situ, revealing minimal recurrence rates when diagnostic excisional biopsies have clear margins, questioning the necessity of routine wide excisions.

AI Clinical Updates Oncology Specialties Urology

AI Foundation Model Revolutionizes Non-Invasive Diagnosis and Grading of Prostate Cancer

By MedXY 09/03/2025

A multidisciplinary Chinese team has developed an AI-driven MRI-pathology foundation model that enables accurate, non-invasive diagnosis and grading of prostate cancer, significantly improving clinical decision-making and reducing unnecessary biopsies.

Gastroenterology news Oncology Specialties

From Silent Struggles to Serious Threats: Understanding Your Liver’s Journey from Hepatitis to Cancer

By MedXY 09/03/2025

Explore how subtle liver symptoms can signal serious illness, the progression from hepatitis to liver cancer, and effective habits to protect your liver health.

Clinical Updates news Oncology

Distinct Clinical and Genomic Profiles of Anogenital Basal Cell Carcinomas Highlight Higher Recurrence Risks

By MedXY 09/01/2025

Anogenital basal cell carcinomas (BCCs) represent a rare subtype with unique genomic features and a higher recurrence rate compared to UV-related BCCs. This French cohort study elucidates their clinical characteristics, lichen sclerosus association, and dependence on the sonic hedgehog pathway, informing tailored management strategies.

Clinical Updates OB/GYN & Women's Health Oncology Specialties

Everolimus Plus Carboplatin: A Promising Combination for Advanced Triple-Negative Breast Cancer

By MedXY 09/01/2025

A phase 2 study shows adding everolimus to carboplatin significantly improves progression-free survival in advanced TNBC with manageable safety profile, indicating a potential new treatment avenue.